-
公开(公告)号：EP3558298A1
公开(公告)日：2019-10-30
申请号：EP17884985.7
申请日：2017-12-15
发明人： MILLER, Michael , CHOBANIAN, Harry, R. , HE, Shuwen , HAO, Jinsong , PIO, Barbara , GUO, Yan , XIAO, Dong
IPC分类号： A61K31/352 , A61K31/353 , A61K31/445
-
公开(公告)号：EP3068389B1
公开(公告)日：2019-10-02
申请号：EP14861985.1
申请日：2014-11-10
发明人： DEMONG, Duane , MILLER, Michael , LIU, Hong , DAI, Xing , GRESHOCK, Thomas, J. , STAMFORD, Andrew , NARGUND, Ravi
IPC分类号： C07D231/56 , C07D401/14 , C07D401/04 , A61K31/415
-
公开(公告)号：EP3102198A1
公开(公告)日：2016-12-14
申请号：EP15745823.3
申请日：2015-02-03
发明人： CHOBANIAN, Harry , DEMONG, Duane , GUO, Yan , HU, Zhiyong , MILLER, Michael , PIO, Barbara , PLUMMER, Christopher, W. , XIAO, Dong , YANG, Cangming , ZHANG, Rui
CPC分类号： C07D211/42 , A61K31/366 , A61K31/397 , A61K31/40 , A61K31/44 , A61K31/4985 , A61K45/06 , C07C59/72 , C07C217/52 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/10 , C07D205/04 , C07D205/12 , C07D207/08 , C07D207/10 , C07D207/12 , C07D209/52 , C07D209/54 , C07D211/22 , C07D213/30 , C07D213/64 , C07D213/647 , C07D213/65 , C07D213/69 , C07D231/20 , C07D239/52 , C07D265/30 , C07D307/86 , C07D307/88 , C07D401/04 , C07D491/056 , A61K2300/00
摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
摘要翻译： 结构式（I）的新型化合物及其药学上可接受的盐是G蛋白偶联受体40（GPR40）的激动剂，可用于治疗，预防和抑制G蛋白偶联受体 受体40.本发明的化合物可用于治疗2型糖尿病，以及通常与该疾病相关的病症，包括肥胖症和脂质疾病，例如混合或糖尿病性血脂异常，高脂血症，高胆固醇血症和 高甘油三酯血症。
-
4.发明公开
公开(公告)号：EP2964222A1
公开(公告)日：2016-01-13
申请号：EP14761134.7
申请日：2014-02-27
发明人： MILLER, Michael , BASU, Kallol , DEMONG, Duane , SCOTT, Jack , LI, Wei , HARRIS, Joel , STAMFORD, Andrew , POIRIER, Marc , TEMPEST, Paul
IPC分类号： A61K31/415 , C07D231/56
CPC分类号： C07D403/14 , A61K31/505 , A61K31/506 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/10 , C07D491/107 , C07D498/08
摘要： The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
-
公开(公告)号：EP3709995A1
公开(公告)日：2020-09-23
申请号：EP18878242.9
申请日：2018-11-12
IPC分类号： A61K31/352 , A61K31/192 , A61K45/06 , C07D213/64
-
公开(公告)号：EP2964221B1
公开(公告)日：2017-12-06
申请号：EP14760677.6
申请日：2014-02-27
发明人： MILLER, Michael , BASU, Kallol , DEMONG, Duane , SCOTT, Jack , LIU, Hong , DAI, Xing , HARRIS, Joel, M. , NEUSTADT, Bernard , STAMFORD, Andrew, W. , POIRIER, Marc , MCCAULEY, John, A. , GRESHOCK, Thomas , STEVENSON, Heather , SANDERS, John , KERN, Jonathan
IPC分类号： A61K31/415 , C07D231/56
CPC分类号： C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D451/02 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/04 , C07D491/056 , C07D491/08 , C07D491/10 , C07D491/107 , C07D491/113 , C07D498/04 , C07D498/08
摘要： The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
-
7.发明公开COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY 有权VERBINDUNGEN ZUR HEMMUNG DERENZYMAKTIVITÄTEINER LEUCINREICHEN REPEAT-KINASE
公开(公告)号：EP2964221A1
公开(公告)日：2016-01-13
申请号：EP14760677.6
申请日：2014-02-27
发明人： MILLER, Michael , BASU, Kallol , DEMONG, Duane , SCOTT, Jack , LIU, Hong , DAI, Xing , HARRIS, Joel, M. , NEUSTADT, Bernard , STAMFORD, Andrew, W. , POIRIER, Marc , MCCAULEY, John, A. , GRESHOCK, Thomas , STEVENSON, Heather , SANDERS, John , KERN, Jonathan
IPC分类号： A61K31/415 , C07D231/56
CPC分类号： C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D451/02 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/04 , C07D491/056 , C07D491/08 , C07D491/10 , C07D491/107 , C07D491/113 , C07D498/04 , C07D498/08
摘要： The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
摘要翻译： 本发明涉及作为LRRK2激酶的有效抑制剂的吲唑化合物，其可用于治疗或预防涉及LRRK2激酶的疾病，例如帕金森病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及LRRK-2激酶的疾病中的用途。
-
8.发明公开SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT 有权取代的环丙基化合物，含有这种化合物的组合物以及治疗方法
公开(公告)号：EP2720544A1
公开(公告)日：2014-04-23
申请号：EP12800485.0
申请日：2012-06-11
发明人： MILLER, Michael , STAMFORD, Andrew , BASU, Kallol , WOOD, Harold, B. , DEMONG, Duane , SUN, Wanying , GARFUNKLE, Joie , MOYES, Christopher , HU, Zhiyong , LIU, Ping , EDMONDSON, Scott, D. , DAI, Xing , DUBOIS, Byron, Gabriel
IPC分类号： A01N43/40 , A61K31/445
CPC分类号： C07D211/24 , C07D211/22 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14
摘要： Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.
摘要翻译： 公开的式I的取代环丙基化合物及其药学上可接受的盐公开用于治疗或预防2型糖尿病和类似病症。 该化合物可用作G蛋白偶联受体GPR-119的激动剂。 药物组合物和治疗方法也包括在内。
-
公开(公告)号：EP3102198B1
公开(公告)日：2020-08-26
申请号：EP15745823.3
申请日：2015-02-03
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.028 秒)
